Maximum quantity allowed is 999
Please select the quantity
CAS RN: 58-32-2 | Product Number: D2274
Dipyridamole
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
- 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakisethanol
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 5G |
NT$2,000
|
35 | ≥40 | It can be shipped in about 3-4 weeks after ordering | |
| 25G |
NT$6,160
|
0 | 7 | It can be shipped in about 3-4 weeks after ordering |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | D2274 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__4H__4__0N__8O__4 = 504.64 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Condition to Avoid | Light Sensitive |
| CAS RN | 58-32-2 |
| Reaxys Registry Number | 68373 |
| PubChem Substance ID | 87568711 |
| SDBS (AIST Spectral DB) | 19363 |
| Merck Index (14) | 3346 |
| MDL Number | MFCD00010555 |
Specifications
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 168 °C |
| Solubility (soluble in) | Chloroform |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H370 : Causes damage to organs. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | KK7450000 |
Transport Information:
| H.S.code* | 2933.99-000 |
Application
Dipyridamole: A Phosphodiesterase (PDE) Inhibitor
Dipyridamole is a phosphodiesterase (PDE) inhibitor.1,2) PDE is a enzyme known to break a phosphodiester bond and degrade cyclic nucleotides. Dipyridamole increases the intracellular levels of cyclic adenosine monophosphate (cAMP) [A2381] and cyclic guanine monophosphate (cGMP) by preventing their conversion to their monophosphates AMP [A0158] and GMP, respectively. Therefore, dipyridamole prevents platelet aggregation by increasing cAMP and cGMP. Furthermore, dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes. This inhibition results in an increase in local concentrations of adenosine thereby stimulating platelet adenylate cyclase and increasing platelet cAMP levels. In clinical, dipyridamole is used as an antithrombotic agent with antiplatelet activity. Recently, it has been suggested that dipyridamole has beneficial effects for the treatment of COVID-19.3,4) (The product is for research purpose only.)
References
- 1) Dipyridamole (a review)
- 2) Translational therapeutics of dipyridamole (a review)
- 3) Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease
- 4) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.